Provided by Tiger Fintech (Singapore) Pte. Ltd.

Trevi Therapeutics, Inc.

6.07
-0.0500-0.82%
Post-market: 6.140.0700+1.15%19:09 EDT
Volume:1.43M
Turnover:8.72M
Market Cap:723.21M
PE:-13.65
High:6.24
Open:6.12
Low:5.98
Close:6.12
Loading ...

Trevi Therapeutics Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
28 May

Oppenheimer Sticks to Its Buy Rating for Trevi Therapeutics (TRVI)

TIPRANKS
·
21 May

Trevi Therapeutics Price Target Maintained With a $24.00/Share by Needham

Dow Jones
·
20 May

BRIEF-Trevi Therapeutics Announces Additional Analyses From Phase 2A River Trial Of Haduvio In Patients With Refractory Chronic Cough

Reuters
·
20 May

Trevi Therapeutics Announces Additional Analyses From Phase 2a River Trial of Haduvio in Patients With Refractory Chronic Cough

THOMSON REUTERS
·
20 May

Stock Track | Trevi Therapeutics Soars 5% After Hours on Strong Q1 Results and Positive Clinical Trial Updates

Stock Track
·
09 May

Trevi Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
09 May

Trevi Therapeutics Reports Q1 2025 Net Loss of $10.3M, Down from $10.9M in 2024; G&A Expenses Rise to $3.7M

Reuters
·
09 May

Trevi Therapeutics Inc: Expected Cash Runway Into Q4 of 2026

THOMSON REUTERS
·
09 May

Trevi Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
07 May

Trevi Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
02 May

Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025

THOMSON REUTERS
·
02 May

Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)

TIPRANKS
·
23 Apr

Trevi Therapeutics Price Target Maintained With a $24.00/Share by Needham

Dow Jones
·
08 Apr

Trevi Therapeutics to Participate in Upcoming April Investor Conferences

PR Newswire
·
03 Apr

BRIEF-Avalo Therapeutics Appoints Michael Heffernan As Chairman Of The Board

Reuters
·
26 Mar

Stock Track | Trevi Therapeutics Soars 6.40% on Strong Q4 Results and Positive Clinical Data in Chronic Cough Treatments

Stock Track
·
19 Mar

Stock Track | Trevi Therapeutics Soars 5.18% Pre-Market on Strong Q4 Results and Positive Clinical Data

Stock Track
·
19 Mar

B.Riley Financial Reaffirms Their Buy Rating on Trevi Therapeutics (TRVI)

TIPRANKS
·
19 Mar

B. Riley Boosts Price Target on Trevi Therapeutics to $20 From $11, Keeps Buy Rating

MT Newswires Live
·
19 Mar